Current status and prospects of HIV treatment

Current Opinion in Virology

Volumn 18, Issue , 2016, Pages 50-56

  Cihlar, Tomas ^a   Fordyce, Marshall ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BMS 955176; CABOTEGRAVIR; CHEMOKINE RECEPTOR CXCR5; DORAVIRINE; EMTRICITABINE; FOSTEMSAVIR; LAMIVUDINE; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY;

ALLELE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS CARRIER; VIRUS LOAD; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; COMBINATION DRUG THERAPY; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; VIROLOGY;

ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84962312463     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.03.004     Document Type: Review

References (49)

1. A. Mocroft, S. Vella, T.L. Benfield, A. Chiesi, V. Miller, P. Gargalianos, A. d'Arminio Monforte, I. Yust, J.N. Bruun, A.N. Phillips, and et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group Lancet 352 1998 1725 1730
2. F.J. Palella Jr., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, D.J. Aschman, and S.D. Holmberg Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 1998 853 860
3. E. Vittinghoff, S. Scheer, P. O'Malley, G. Colfax, S.D. Holmberg, and S.P. Buchbinder Combination antiretroviral therapy and recent declines in AIDS incidence and mortality J Infect Dis 179 1999 717 720
4. Antiretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies Lancet 372 2008 293 299
5. W.A. O'Brien, P.M. Hartigan, D. Martin, J. Esinhart, A. Hill, S. Benoit, M. Rubin, M.S. Simberkoff, and J.D. Hamilton Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS N Engl J Med 334 1996 426 431
6. F. Garcia, M. Plana, M. Arnedo, M. Brunet, P. Castro, C. Gil, E. Vidal, O. Millan, A. Lopez, J. Martorell, and et al. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: A randomized pilot study J Acquir Immune Defic Syndr 36 2004 823 830
7. T.E. Yamashita, J.P. Phair, A. Munoz, J.B. Margolick, R. Detels, S.J. O'Brien, J.W. Mellors, S.M. Wolinsky, and L.P. Jacobson Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study AIDS 15 2001 735 746
8. Center for Disease Control and Prevention Rev ed. HIV/AIDS Surveillance Report, 2005 17 2007 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention pp. 1-54. Also available at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/
9. R.M. Selik, R.H. Byers Jr., and M.S. Dworkin Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999 J Acquir Immune Defic Syndr 29 2002 378 387
10. G. Guaraldi, G. Orlando, S. Zona, M. Menozzi, F. Carli, E. Garlassi, A. Berti, E. Rossi, A. Roverato, and F. Palella Premature age-related comorbidities among HIV-infected persons compared with the general population Clin Infect Dis 53 2011 1120 1126
11. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population J Acquir Immune Defic Syndr 46 2007 72 77
12. A. Mocroft, O. Kirk, P. Reiss, S. De Wit, D. Sedlacek, M. Beniowski, J. Gatell, A.N. Phillips, B. Ledergerber, J.D. Lundgren, and et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients AIDS 24 2010 1667 1678
13. P. Morlat, A. Vivot, M.A. Vandenhende, F.A. Dauchy, J. Asselineau, E. Deti, Y. Gerard, E. Lazaro, P. Duffau, D. Neau, and et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012 PloS ONE 8 2013 e66223
14. G.A. McComsey, D. Kitch, E.S. Daar, C. Tierney, N.C. Jahed, P. Tebas, L. Myers, K. Melbourne, B. Ha, and P.E. Sax Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202 J Infect Dis 203 2011 1791 1801
15. ® (tenofovir disoproxil fumarate) powder, for oral use 2013 U.S. Prescribing Information
16. P.J. Ruane, E. DeJesus, D. Berger, M. Markowitz, U.F. Bredeek, C. Callebaut, L. Zhong, S. Ramanathan, M.S. Rhee, M.W. Fordyce, and et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults J Acquir Immune Defic Syndr 63 2013 449 455
17. C.A. Sabin, S.W. Worm, R. Weber, P. Reiss, W. El-Sadr, F. Dabis, S. De Wit, M. Law, A. D'Arminio Monforte, N. Friis-Moller, and et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration Lancet 371 2008 1417 1426
18. N. Obel, D.K. Farkas, G. Kronborg, C.S. Larsen, G. Pedersen, A. Riis, C. Pedersen, J. Gerstoft, and H.T. Sorensen Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: A population-based nationwide cohort study HIV Med 11 2010 130 136
19. A.I. Choi, E. Vittinghoff, S.G. Deeks, C.C. Weekley, Y. Li, and M.G. Shlipak Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons AIDS 25 2011 1289 1298
20. J. Prejean, R. Song, A. Hernandez, R. Ziebell, T. Green, F. Walker, L.S. Lin, Q. An, J. Mermin, A. Lansky, and et al. Estimated HIV incidence in the United States, 2006-2009 PloS ONE 6 2011 e17502
21. J.M. Baeten, E. Kahle, J.R. Lingappa, R.W. Coombs, S. Delany-Moretlwe, E. Nakku-Joloba, N.R. Mugo, A. Wald, L. Corey, D. Donnell, and et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission Sci Transl Med 3 2011 77ra29
22. P.M. Sheth, C. Kovacs, K.S. Kemal, R.B. Jones, J.M. Raboud, R. Pilon, C. la Porte, M. Ostrowski, M. Loutfy, H. Burger, and et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy AIDS 23 2009 2050 2054
23. S.M. Graham, S.E. Holte, N.M. Peshu, B.A. Richardson, D.D. Panteleeff, W.G. Jaoko, J.O. Ndinya-Achola, K.N. Mandaliya, J.M. Overbaugh, and R.S. McClelland Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding AIDS 21 2007 501 507
24. S. Attia, M. Egger, M. Muller, M. Zwahlen, and N. Low Sexual transmission of HIV according to viral load and antiretroviral therapy: Systematic review and meta-analysis AIDS 23 2009 1397 1404
25. M. Das, P.L. Chu, G.M. Santos, S. Scheer, E. Vittinghoff, W. McFarland, and G.N. Colfax Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco PloS ONE 5 2010 e11068
26. J.S. Montaner, V.D. Lima, R. Barrios, B. Yip, E. Wood, T. Kerr, K. Shannon, P.R. Harrigan, R.S. Hogg, P. Daly, and et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: A population-based study Lancet 376 2010 532 539
27. T.C. Porco, J.N. Martin, K.A. Page-Shafer, A. Cheng, E. Charlebois, R.M. Grant, and D.H. Osmond Decline in HIV infectivity following the introduction of highly active antiretroviral therapy AIDS 18 2004 81 88
28. M.S. Cohen, Y.Q. Chen, M. McCauley, T. Gamble, M.C. Hosseinipour, N. Kumarasamy, J.G. Hakim, J. Kumwenda, B. Grinsztejn, J.H. Pilotto, and et al. Prevention of HIV-1 infection with early antiretroviral therapy N Engl J Med 365 2011 493 505
29. K.R. Calvo, and E.S. Daar Antiretroviral therapy: Treatment-experienced individuals Infect Dis Clin North Am 28 2014 439 456
30. P.E. Sax, E. DeJesus, A. Mills, A. Zolopa, C. Cohen, D. Wohl, J.E. Gallant, H.C. Liu, L. Zhong, K. Yale, and et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks Lancet 379 2012 2439 2448
31. E. DeJesus, J.K. Rockstroh, K. Henry, J.M. Molina, J. Gathe, S. Ramanathan, X. Wei, K. Yale, J. Szwarcberg, K. White, and et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial Lancet 379 2012 2429 2438
32. S.L. Walmsley, A. Antela, N. Clumeck, D. Duiculescu, A. Eberhard, F. Gutierrez, L. Hocqueloux, F. Maggiolo, U. Sandkovsky, C. Granier, and et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection N Engl J Med 369 2013 1807 1818
33. E.S. Daar, C. Tierney, M.A. Fischl, P.E. Sax, K. Mollan, C. Budhathoki, C. Godfrey, N.C. Jahed, L. Myers, D. Katzenstein, and et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1 Ann Intern Med 154 2011 445 456
34. S. Walmsley, A. Baumgarten, J. Berenguer, F. Felizarta, E. Florence, M.A. Khuong-Josses, J.M. Kilby, T. Lutz, D. Podzamczer, J. Portilla, and et al. Brief report: Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: Week 96 and week 144 results from the SINGLE randomized clinical trial J Acquir Immune Defic Syndr 70 2015 515 519
35. A.M. Margolis, H. Heverling, P.A. Pham, and A. Stolbach A review of the toxicity of HIV medications J Med Toxicol 10 2014 26 39
36. P.E. Sax, D. Wohl, M.T. Yin, F. Post, E. DeJesus, M. Saag, A. Pozniak, M. Thompson, D. Podzamczer, J.M. Molina, and et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials Lancet 385 2015 2606 2615
37. M.T. Lai, M. Feng, J.P. Falgueyret, P. Tawa, M. Witmer, D. DiStefano, Y. Li, J. Burch, N. Sachs, M. Lu, and et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor Antimicrob Agents Chemother 58 2014 1652 1663
38. D. Schurmann, C. Sobotha, J. Gilmartin, M. Robberechts, I. De Lepeleire, K.L. Yee, Y. Guo, R. Liu, F. Wagner, J.A. Wagner, and et al. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals AIDS 30 2016 57 63
39. J.M. Gatell, J.O. Morales-Ramirez, D.P. Hagins, M. Thompson, A. Keikawus, C. Hoffmann, S. Rugina, O. Osiyemi, S. Escoriu, R. Dretler, and et al. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients J Int AIDS Soc 17 Suppl. 3 2014 19532
40. S.L. Ford, E. Gould, S. Chen, D. Margolis, W. Spreen, H. Crauwels, and S. Piscitelli Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744 Antimicrob Agents Chemother 57 2013 5472 5477
41. W. Spreen, S. Min, S.L. Ford, S. Chen, Y. Lou, M. Bomar, M. St Clair, S. Piscitelli, and T. Fujiwara Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor HIV Clin Trials 14 2013 192 203
42. C. Trezza, S.L. Ford, W. Spreen, R. Pan, and S. Piscitelli Formulation and pharmacology of long-acting cabotegravir Curr Opin HIV AIDS 10 2015 239 245
43. B. Nowicka-Sans, Y.F. Gong, B. McAuliffe, I. Dicker, H.T. Ho, N. Zhou, B. Eggers, P.F. Lin, N. Ray, M. Wind-Rotolo, and et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068 Antimicrob Agents Chemother 56 2012 3498 3507
44. D.R. Langley, S.R. Kimura, P. Sivaprakasam, N. Zhou, I. Dicker, B. McAuliffe, T. Wang, J.F. Kadow, N.A. Meanwell, and M. Krystal Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action Proteins 83 2015 331 350
45. M. Caskey, F. Klein, J.C. Lorenzi, M.S. Seaman, A.P. West Jr., N. Buckley, G. Kremer, L. Nogueira, M. Braunschweig, J.F. Scheid, and et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 Nature 522 7557 2015 487 491
46. R.M. Lynch, E. Boritz, E.E. Coates, A. DeZure, P. Madden, P. Costner, M.E. Enama, S. Plummer, L. Holman, C.S. Hendel, and et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection Sci Transl Med 7 2015 319ra206
47. R. Gulick HIV treatment 2020: What will it look like? J Int AIDS Soc 17 Suppl. 3 2014 19528
48. N.M. Archin, J.M. Sung, C. Garrido, N. Soriano-Sarabia, and D.M. Margolis Eradicating HIV-1 infection: Seeking to clear a persistent pathogen Nat Rev Microbiol 12 2014 750 764
49. T.W. Chun, S. Moir, and A.S. Fauci HIV reservoirs as obstacles and opportunities for an HIV cure Nat Immunol 16 2015 584 589